Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06660810 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Intralesional Injection of Talimogene Laherparepvec
A Phase 2 study of Soft Tissue Sarcoma and Sarcoma,Soft Tissue, sponsored by John Rieth.
- Active
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
- 1
- Study location
NCT06660810 is a Phase 2 study of Soft Tissue Sarcoma and Sarcoma,Soft Tissue that is active but no longer recruiting, run by John Rieth. The registered enrollment target is 2 participants, below the 79-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06660810, a Phase 2 study of Soft Tissue Sarcoma and Sarcoma,Soft Tissue, is active but no longer recruiting, sponsored by John Rieth.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed study is designed to treat locally advanced soft tissue sarcoma (STS) subtypes with neoadjuvant talimogene laherparepvec (TVEC) and preoperative external beam radiation therapy (EBRT).
Conditions Studied
Interventions
- PROCEDURE Surgery
- DRUG Talimogene Laherparepvec
- RADIATION Neoadjuvant Radiation
Study Locations (1)
Iowa
- University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2025-03-03 |
| Est. Completion | 2030-03-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06660810
The ClinicalTrials.gov registry entry for NCT06660810 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 79-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (97% lower). The listed sponsor is John Rieth, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Soft Tissue Sarcoma appearing as the primary indexed condition, and to 3 interventions - of which Surgery is the first listed.
NCT06660810 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.
Frequently Asked Questions
What is clinical trial NCT06660810 about?
NCT06660810 is a clinical study titled "Neoadjuvant Intralesional Injection of Talimogene Laherparepvec". The proposed study is designed to treat locally advanced soft tissue sarcoma (STS) subtypes with neoadjuvant talimogene laherparepvec (TVEC) and preoperative external beam radiation therapy (EBRT).
What is the current status of trial NCT06660810?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2025-03-03. Estimated completion is 2030-03-10.
What conditions does trial NCT06660810 study?
This clinical trial studies the following conditions: Soft Tissue Sarcoma, Sarcoma,Soft Tissue.
What interventions are being tested in trial NCT06660810?
The interventions under investigation include: Surgery (PROCEDURE), Talimogene Laherparepvec (DRUG), Neoadjuvant Radiation (RADIATION).
Who is sponsoring clinical trial NCT06660810?
This trial is sponsored by John Rieth, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06660810 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Soft Tissue Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma
RECRUITING · Phase 2
-
Preoperative 5-Day Radiotherapy for Soft Tissue Sarcoma
RECRUITING · Phase 2
-
Hypofractionated vs Conventional Fractionated RT in Soft Tissue Sarcomas
RECRUITING · Phase 2
-
SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma
RECRUITING · Phase 2
-
5-Day Preoperative Radiation for Soft Tissue Sarcoma
RECRUITING · Phase 2
-
Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.